Table 1.

Patient characteristics and BAE procedural information

Characteristics	No. of patients (n = 61)
Age, mean (range)	69 (31–87)
Sex, male/female	24/37
Smoking status, current/ex/never	6/20/35
Body mass index, mean (SD)	20.02 (3.4)
Haemoptysis, mild/moderate/massive	8/14/39
Comorbidity
Hypertension	14
Malignant disease	7 (hepatocellular carcinoma, 2 cases; oesophageal cancer, 1 case; breast cancer, 1 case; lung cancer, 1 case; bladder cancer, 1 case; prostate cancer, 1 case)
Connective tissue disease	6
COPD	6
Bronchial asthma	6
Previous cerebral infarction	4
Ischaemic heart disease	3
Diabetes mellitus	3
HIV infection	1
Epilepsy	1
Interstitial pneumonia	1
Baseline diseases
Bronchiectasis/cystic fibrosis	18
NTM	17
Cryptogenic haemoptysis	16
Pulmonary aspergillosis	8
Pulmonary TB sequelae	2
mMRC before BAE (0/1/2/3/4)	12/11/17/12/9
Procedural information for BAE
Initial/recurrent treatment	37/24
Procedural success rate (%)	198/203 (98%)
Length of hospital stay	5.8 days (95% CI, 4.6–7.1)
Complications	Major complication, none Minor complications: mediastinal haematoma, 1 case; chest pain, 1 case; back pain, 1 case; vomiting, 2 cases; extravasation, 2 cases; vagal reflex, 2 cases
Recurrence-free haemoptysis rate at 6 months	91.8% (95% CI, 91.1–92.5)

CI, confidence interval; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; NTM, non-tuberculous mycobacteria; TB, tuberculosis; mMRC, modified Medical Research Council dyspnoea scale; BAE, bronchial artery embolisation